MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. TALK
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Talkspace (TALK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Talkspace
NasdaqCM•Healthcare•Health Information Services
$5.250.00(0.00%)Market closed
Market Cap
$879.30M
P/E
4532.5x
P/S
3.6x
P/B
7.8x

Talkspace, Inc., together with its subsidiaries, operates as a virtual behavioral healthcare company that connects patients with licensed mental health providers in the United States. The company provides psychotherapy and psychiatry services to treat various mental health conditions, such as depression, anxiety, trauma, and other fields of human challenges by operating an online platform for one-on-one therapy delivered through messaging, audio, and video channels. It serves health insurance plans and employee assistance programs, direct-to-enterprise customers, and individual subscribers. The company was formerly known as Groop Internet Platform Inc. and changed its name to Talkspace, Inc. in June 2021. The company was founded in 2012 and is headquartered in New York, New York.

C

How this company scores

AverageMetricSide Score: 57/100

Strongest: Cash & Earnings Quality (20/25); weakest: Profitability (5/25).

Profitability5/25
Growth17/25
Balance Sheet & Red Flags15/25
Cash & Earnings Quality20/25
Strengths
Growing revenueRising free cash flowInterest easily coveredConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 4532.5x5y range 111.1x – 4532.5x
P/E 4532.5x · above its 7-quarter median

Currently above its 7-quarter median.

P/S · 3.6x5y range 3.6x – 13.8x
P/S 3.6x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 7.8x5y range 2.4x – 7.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $879.30M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$245.73M
7Q
Q. Revenue
$61.67M
2Q
TTM EBITDA
$1.41M
452%
TTM Op. Income
$-3.21M
2Q
Q. Op. Income
$-2.11M
18%
TTM Net Income
$194,000
2Q
Q. Net Income
$-1.52M
180%
EPS
$-0.01
Shares Out.
$167.49M
2Q
$245.73M in TTM revenue grew 21.3% YoY, reaching $61.67M last quarter. TTM EBITDA of $1.41M and TTM operating income of $-3.21M show growth is flowing through to the bottom line. TTM net income of $194,000 means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
40.2%
2Q
EBITDA Margin
-0.9%
57%
Op. Margin
-3.4%
4%
Net Margin
-2.5%
147%
Op. margin of -3.4% is down 0.1% YoY — costs are rising relative to revenue. Net margin at -2.5% and gross margin of 40.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 4% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
4532.5x
2Q
P/S Ratio
3.6x
7Q
P/B Ratio
7.8x
2Q
At 4532.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.6x and P/B of 7.8x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 7 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$136.45M
3Q
Cash
$39.16M
28%
Long-Term Debt
N/A
Book Value
$112.13M
2Q
D/E Ratio
N/A
Debt/EBITDA
N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$11.38M
3344%
TTM Free Cash Flow
$4.61M
429%
FCF Margin
1.9%
336%
FCF / Net Income
23.8
7716%
TTM FCF of $4.61M on $11.38M in operating cash flow. The FCF / Net Income ratio of 23.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 429% — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 7.8x
· near its 20-quarter median

Currently near its 20-quarter median.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.